Tags

Type your tag names separated by a space and hit enter

Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians.
Ann Intern Med 2017; 166(1):58-68AIM

Abstract

Description

The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the management of gout.

Methods

Using the ACP grading system, the committee based these recommendations on a systematic review of randomized, controlled trials; systematic reviews; and large observational studies published between January 2010 and March 2016. Clinical outcomes evaluated included pain, joint swelling and tenderness, activities of daily living, patient global assessment, recurrence, intermediate outcomes of serum urate levels, and harms.

Target Audience and Patient Population

The target audience for this guideline includes all clinicians, and the target patient population includes adults with acute or recurrent gout.

Recommendation 1

ACP recommends that clinicians choose corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or colchicine to treat patients with acute gout. (Grade: strong recommendation, high-quality evidence).

Recommendation 2

ACP recommends that clinicians use low-dose colchicine when using colchicine to treat acute gout. (Grade: strong recommendation, moderate-quality evidence).

Recommendation 3

ACP recommends against initiating long-term urate-lowering therapy in most patients after a first gout attack or in patients with infrequent attacks. (Grade: strong recommendation, moderate-quality evidence).

Recommendation 4

ACP recommends that clinicians discuss benefits, harms, costs, and individual preferences with patients before initiating urate-lowering therapy, including concomitant prophylaxis, in patients with recurrent gout attacks. (Grade: strong recommendation, moderate-quality evidence).

Authors+Show Affiliations

From the American College of Physicians and University of Pennsylvania Health System, Philadelphia, Pennsylvania, and University of North Carolina School of Medicine, Chapel Hill, North Carolina.From the American College of Physicians and University of Pennsylvania Health System, Philadelphia, Pennsylvania, and University of North Carolina School of Medicine, Chapel Hill, North Carolina.From the American College of Physicians and University of Pennsylvania Health System, Philadelphia, Pennsylvania, and University of North Carolina School of Medicine, Chapel Hill, North Carolina.No affiliation info available

Pub Type(s)

Journal Article
Practice Guideline

Language

eng

PubMed ID

27802508

Citation

Qaseem, Amir, et al. "Management of Acute and Recurrent Gout: a Clinical Practice Guideline From the American College of Physicians." Annals of Internal Medicine, vol. 166, no. 1, 2017, pp. 58-68.
Qaseem A, Harris RP, Forciea MA, et al. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017;166(1):58-68.
Qaseem, A., Harris, R. P., & Forciea, M. A. (2017). Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. Annals of Internal Medicine, 166(1), pp. 58-68. doi:10.7326/M16-0570.
Qaseem A, et al. Management of Acute and Recurrent Gout: a Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Jan 3;166(1):58-68. PubMed PMID: 27802508.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. AU - Qaseem,Amir, AU - Harris,Russell P, AU - Forciea,Mary Ann, AU - ,, Y1 - 2016/11/01/ PY - 2016/11/2/pubmed PY - 2017/5/13/medline PY - 2016/11/2/entrez SP - 58 EP - 68 JF - Annals of internal medicine JO - Ann. Intern. Med. VL - 166 IS - 1 N2 - Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the management of gout. Methods: Using the ACP grading system, the committee based these recommendations on a systematic review of randomized, controlled trials; systematic reviews; and large observational studies published between January 2010 and March 2016. Clinical outcomes evaluated included pain, joint swelling and tenderness, activities of daily living, patient global assessment, recurrence, intermediate outcomes of serum urate levels, and harms. Target Audience and Patient Population: The target audience for this guideline includes all clinicians, and the target patient population includes adults with acute or recurrent gout. Recommendation 1: ACP recommends that clinicians choose corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or colchicine to treat patients with acute gout. (Grade: strong recommendation, high-quality evidence). Recommendation 2: ACP recommends that clinicians use low-dose colchicine when using colchicine to treat acute gout. (Grade: strong recommendation, moderate-quality evidence). Recommendation 3: ACP recommends against initiating long-term urate-lowering therapy in most patients after a first gout attack or in patients with infrequent attacks. (Grade: strong recommendation, moderate-quality evidence). Recommendation 4: ACP recommends that clinicians discuss benefits, harms, costs, and individual preferences with patients before initiating urate-lowering therapy, including concomitant prophylaxis, in patients with recurrent gout attacks. (Grade: strong recommendation, moderate-quality evidence). SN - 1539-3704 UR - https://www.unboundmedicine.com/medline/citation/27802508/full_citation L2 - https://www.annals.org/article.aspx?doi=10.7326/M16-0570 DB - PRIME DP - Unbound Medicine ER -